Market Intelligence, Clinical Progress, and High-Purity Reagents for Hepatocellular Carcinoma & Solid Tumor Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TM4SF5 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TM4SF5 LEL (Large Extracellular Loop) Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed. |
View TM4SF5 Products |
| Gene Delivery | TM4SF5 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Essential for multi-pass conformation preservation. |
View TM4SF5 Products |
| Benchmark Ab | Anti-TM4SF5 Recombinant Antibody Recombinant positive control based on clinical benchmark clones (e.g., clone 2D4). |
View TM4SF5 Products |
| Validator | TM4SF5 siRNA Set For target knockdown verification in functional assays. |
View TM4SF5 Products |
| Related Target A | EGFR TM4SF5 physically associates with EGFR to promote EMT, migration, and resistance to EGFR inhibitors. |
View EGFR Products |
| Related Target B | Integrin alpha 5 (ITGA5) TM4SF5 forms complexes with integrins (α5β1) to regulate cell adhesion and metastatic signaling. |
View ITGA5 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-pass membrane protein conformation loss | Lentivirus-mediated stable cell line construction preserves native 4-transmembrane structure. |
| Cross-reactivity with other TM4SF family members | Sequence-verified LEL domain recombinant proteins for rigorous counter-screening panels. |
| Lack of clinical-grade positive controls | Sequence-defined recombinant benchmark antibodies available for binding and functional assays. |
| Assay specificity validation | Pre-designed, high-knockdown efficiency siRNA sets included for target validation. |
Live TM4SF5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TM4SF5 therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and CAR-T cell therapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting multi-pass epitope-specific binding to bypass drug resistance in hepatocellular carcinoma (HCC) and colon cancer. TM4SF5 has emerged as a key driver of epithelial-mesenchymal transition (EMT) and resistance to tyrosine kinase inhibitors (such as sorafenib), making it a highly attractive target for combination regimens.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugates (ADC) | Biotech Startups, Academic Institutions | Hepatocellular Carcinoma (HCC), Colon Cancer | Internalization Assay (Need high-purity TM4SF5 LEL-Fc for binding & internalization screening) |
| Monoclonal Antibodies (mAbs) | Oncology-focused Biopharma | Metastatic Solid Tumors, Pancreatic Cancer | Epitope Mapping & Specificity (Need Lentivirus for cell-based Flow Cytometry assays) |
| CAR-T / Cell Therapy | Cell Therapy Developers | Refractory Liver Cancer | In vitro target cell killing assay (Need stable overexpressing cell lines via Lentivirus) |